You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金城醫藥(300233.SZ)2019年度淨利潤降22.96%至2.03億元 擬10派2元
格隆匯 04-20 22:23

格隆匯4月20日丨金城醫藥(300233.SZ)發佈2019年年度報告,實現營業收入27.95億元,同比下降7.09%;歸屬於上市公司股東的淨利潤2.03億元,同比下降22.96%;歸屬於上市公司股東的扣除非經常性損益的淨利潤6462.19萬元,同比下降74.25%;基本每股收益0.52元,擬每10股派發現金紅利2元(含税)。

2019年度,子公司金城泰爾受醫藥行業政策及市場競爭等多方面因素影響,未完成預期業績目標,計提商譽減值準備2.89億元,從而影響了公司整體業績。

報告期內,公司業務主要涉及醫藥中間體、生物原料藥、終端製劑等三大領域,主營業務包括頭孢粉針製劑、頭孢側鏈中間體、生物特色原料藥、婦兒科終端製劑等相關藥品的生產、研發與銷售;報告期內,在公司鑄鏈工程的推動下,公司發揮產業鏈協同優勢,積極佈局原料藥產業,組建原料藥研發隊伍及平台。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account